학술논문
A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics.
Document Type
Article
Author
Ming, Jeffrey E.; Abrams, Ruth E.; Bartlett, Derek W.; Mengdi Tao; Tu Nguyen; Surks, Howard; Kudrycki, Katherine; Kadambi, Ananth; Friedrich, Christina M.; Djebli, Nassim; Goebel, Britta; Koszycki, Alex; Varshnaya, Meera; Elassal, Joseph; Banerjee, Poulabi; Sasiela, William J.; Reed, Michael J.; Barrett, Jeffrey S.; Azer, Karim
Source
Subject
*CHOLESTEROL metabolism
*STATINS (Cardiovascular agents)
*PROPROTEIN convertases
*CARDIOVASCULAR diseases
*DYSLIPIDEMIA
*
*
*
*
Language
ISSN
1177-6250
Abstract
Reduction in low-density lipoprotein cholesterol (LDL-C) is associated with decreased risk for cardiovascular disease. Alirocumab, an antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduces LDL-C. Here, we report development of a quantitative systems pharmacology (QSP) model integrating peripheral and liver cholesterol metabolism, as well as PCSK9 function, to examine the mechanisms of action of alirocumab and other lipid-lowering therapies, including statins. The model predicts changes in LDL-C and other lipids that are consistent with effects observed in clinical trials of single or combined treatments of alirocumab and other treatments. An exploratory model to examine the effects of lipid levels on plaque dynamics was also developed. The QSP platform, on further development and qualification, may support dose optimization and clinical trial design for PCSK9 inhibitors and lipid-modulating drugs. It may also improve our understanding of factors affecting therapeutic responses in different phenotypes of dyslipidemia and cardiovascular disease. [ABSTRACT FROM AUTHOR]